China Traditional Chinese Medicine Possible Privatisation

China Traditional Chinese Med (570 HK): Third Time's the Charm as Sinopharm Revives Its Interest?

Weekly Deals Digest (11 Feb) - Lawson, Benefit One, Welbe, China TCM, L'Occitane, Hollysys

A Growing Market, Government Backing: What's Not to Like?

Trad Chi Med (570 HK): Sinopharm's Feverish Proposal

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Event-Driven

China Traditional Chinese Medicine / Event-Driven

China Traditional Chinese Medicine (570 HK)

<p>In light of the proposed privatisation of China TCM, this Insight briefly discusses precedent transactions involving China pharmaceutical companies and some of the issues that have weighed on the shares' valuation. Precedent transaction data argue for a much higher valuation, but the buyers have substantial leverage in this case.</p>

In light of the proposed privatisation of China TCM, this Insight briefly discusses precedent transactions involving China pharmaceutical companies and some of the issues that have weighed on the shares' valuation. Precedent transaction data argue for a much higher valuation, but the buyers have substantial leverage in this case.

Trad Chi Med (570 HK): Additional Thoughts